IMMX Strangle Strategy
IMMX (Immix Biopharma, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications.
IMMX (Immix Biopharma, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $618.5M, a beta of 0.11 versus the broader market, a 52-week range of 1.94-12.14, average daily share volume of 1.5M, a public-listing history dating back to 2021, approximately 21 full-time employees. These structural characteristics shape how IMMX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.11 indicates IMMX has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on IMMX?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
IMMX snapshot
As of August 14, 2026, spot at $10.90, ATM IV 108.30%, IV rank 19.41%, expected move 31.05%. The strangle on IMMX below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this strangle structure on IMMX specifically: IMMX IV at 108.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a IMMX strangle, with a market-implied 1-standard-deviation move of approximately 31.05% (roughly $3.38 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IMMX expiries trade a higher absolute premium for lower per-day decay. Position sizing on IMMX should anchor to the underlying notional of $10.90 per share and to the trader's directional view on IMMX stock.
IMMX strangle setup
The IMMX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IMMX at $10.90 on that close, the first option leg uses a $11.45 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IMMX chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IMMX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $11.45 | N/A |
| Buy 1 | Put | $10.36 | N/A |
IMMX strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
IMMX strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on IMMX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on IMMX
Strangles on IMMX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IMMX chain.
IMMX thesis for this strangle
The market-implied 1-standard-deviation range for IMMX extends from approximately $7.52 on the downside to $14.28 on the upside. A IMMX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current IMMX IV rank near 19.41% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on IMMX at 108.30%. As a Healthcare name, IMMX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IMMX-specific events.
IMMX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IMMX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IMMX alongside the broader basket even when IMMX-specific fundamentals are unchanged. Always rebuild the position from current IMMX chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on IMMX?
- A strangle on IMMX is the strangle strategy applied to IMMX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With IMMX stock at $10.90 on the most recent close, the strikes shown on this page are snapped to the nearest listed IMMX chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are IMMX strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the IMMX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 108.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a IMMX strangle?
- The breakeven for the IMMX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The IMMX market-implied 1-standard-deviation expected move in the same options snapshot is approximately 31.05%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on IMMX?
- Strangles on IMMX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IMMX chain.
- How does current IMMX implied volatility affect this strangle?
- IMMX ATM IV is at 108.30% with IV rank near 19.41%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.